Update on the management of variceal bleeding

Scottish Medical Journal

Volumn 50, Issue 1, 2005, Pages 5-10

  Goshi, N G ^a   Stanley, Adrian J ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CYANOACRYLATE; ENBUCRILATE; GLYCERYL TRINITRATE; ISOSORBIDE MONONITRATE; NITRATE; OCTREOTIDE; PLACEBO; PROPRANOLOL; SOMATOSTATIN; TERLIPRESSIN; THROMBIN; VASOPRESSIN;

AIRWAY CONDUCTANCE; ALCOHOL ABUSE; ARTICLE; ASPIRATION PNEUMONIA; BACTEREMIA; BALLOON; BALLOON CATHETER; BLOOD CLOTTING DISORDER; BOLUS INJECTION; BRAIN DISEASE; BRAIN EMBOLISM; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; CRYOPRECIPITATE; DESENSITIZATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENDOSCOPIC SCLEROTHERAPY; ENDOSCOPIC THERAPY; ESOPHAGUS STRICTURE; ESOPHAGUS VARICES BLEEDING; FLUID THERAPY; GASTROINTESTINAL ENDOSCOPY; HEART DISEASE; HEPATIC VEIN; HUMAN; INTERMETHOD COMPARISON; INTESTINE PERFORATION; INTESTINE ULCER; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LUNG EMBOLISM; METHODOLOGY; MORTALITY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PREDICTION; PRESSURE GRADIENT; RECURRENCE RISK; RECURRENT DISEASE; RESUSCITATION; RETROPERITONEAL ABSCESS; RISK FACTOR; SEPSIS; SIDE EFFECT; SPLEEN INFARCTION; STOMACH VARICES; SURVIVAL RATE; SYSTEMIC DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; VARICOSIS; VEIN LIGATION; VENOUS PRESSURE;

EID: 15844423878     PISSN: 00369330     EISSN: None     Source Type: Journal    
DOI: 10.1177/003693300505000102     Document Type: Article

References (87)

1. Laine L.Upper gastrointestinal tract hemorrhage. West JMed 1991; 155:274-9.
2. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988;319:983-9.
3. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranalol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-7.
4. Lebrec D, Poynard T, Bernuau J, et al. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984;4:355-8.
5. Colombo M, De Franchis R, Tommasini M, Sangiovanni A, Dioguardi N. Beta blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: A multicenter randomized controlled trial. Hepatology 1989;9:433-8.
6. Garden OJ, Mills PR, Birnie GG, Murray GD, Carter DC. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. Gastroenterology 1990;98:185-90.
7. Garden OJ, Motyl H, Gilmour WH, et al. Prediction of outcome following acute variceal haemorrhage. Br J Surg 1985;72:91-5.
8. Williams SGJ, Westaby D. Management of variceal hemorrhage. Br Med J 1994;308:1213-7.
9. Ueno T, Inuzuka S, Torimura T, et al. Distribution of substance P and vasoactive intestinal peptide in the human liver: light and electron immunoperoxidase methods of observation. Am J Gastroenterol. 1991;86:1633-7.
10. Feher E, Fodor M, Feher J. Ultrastructural localization of somatostatin -and substance P-immunoreactive nerve fibre in the feline liver. Gastroenterology 1992; 102:287-94.
11. Irle C, Kocher O, Cabbiani G. Contractility of myofibroblasts during experimental liver cirrhosis. J Submicrosc Cytol Pathol. 1980;12:209-17.
12. Tsai YT, Lin HC, Yang MCM, et al. Plasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function. J. Hepatol. 1995;23:681-88.
13. Asbert M, Gines A, Gines P, et al. Circulating level of endothelin in cirrhosis. Gastroenterology 1993;104:1485-91.
14. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implication for regulation of portal pressure and resistance. Hepatology 1996:24:233-40.
15. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis 1986;6:318-31.
16. Lebrec D, De Fleury P, Rueff B, Nahum H, Benhamou JP. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 1980;79:1139-44.
17. Garcia Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastrointestinal varices and variceal bleeding. Hepatology 1985;5:419-24.
18. Kravetz D , Bosch J, Arderiu M, et al. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: Influence of the extent of portal-systemic shunting. Hepatology 1989;9:808-14.
19. Bernard B, Cadranel J-F, Valle D, et al. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995;108:1828-34.
20. Goulis J, Armonis A, Patch D, Sabin C. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998;27:1207-12.
21. Bernard B, Grange J-D, Nyugen K E, Xavier A, Pierre O, Thierry P. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29:1655-61.
22. Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2000;46:iii1-iii15.
23. Rodriguez-Perez F, Groszmann RJ. Pharmacologic treatment of portal hypertension. Gastroenterol Clin North Am 1992;21:15-40.
24. Freeman JG, Cobden MD, Record CO. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. J Clin Gastroenterol 1989;11:58-60.
25. Soderlund C, Magnusson I, Torngren S, Lundell L. Terlipressin (triglycyllysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 1990;25:622-30.
26. Escorsell A, Ruiz del Arbol L, Planes R, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: The TEST study. Hepatology 2000;32:471-6.
27. Feu F, Ruiz del Arbol L, Banares R, Bosch J. Double blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Gastroenterology 1996;111:1291-9.
28. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage (Cochrane Review). Cochrane Database of Systematic Reviews(1):CD002147, 2003.
29. Jenkins SA, Shields R, Davies M, et al. A multicentre randomized trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997;41:526-33.
30. Besson I, Ingrand P, Person B, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Eng j Med 1995;333:550-60.
31. Sung JJ, Chung SC, Yung MY, et al. Prospective randomized study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995;346:1666-9.
32. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001;120:161-9.
33. Burroughs AK. Double blind randomized clinical trial of 5 day octreotide versus placebo associated sclerotherapy for treatment failures. Hepatology 1996;24:901.
34. Westaby D, Hayes PC, Gimson AE, Polson RJ, Williams R. Controlled clinical trial of injection sclerotherapy for active variceal bleeding. Hepatology 1989;9:274-7.
35. Lo GH, Lai KH, Ng WW, et al. Injection sclerotherapy preceded by esophageal tamponade versus immediate sclerotherapy in arresting active variceal bleeding: a prospective randomized trial. Gastrointest Endosc1992;38:421-4.
36. Lo GH, Lai KH, Cheng JS, et al. Emergency Banding ligation versus sclerotherapy for the controlled bleeding of esophageal varices. Hepatology 1997;25:1101-4.
37. Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992;326:1527-32.
38. Fort E, Sautereau D, Silvain C, Ingrand P, Pilligand B, Beauchant M. A randomized trial of terlipressin plus nitroglycerine vs. balloon tamponade in the acute variceal bleeding. Hepatology 1990;11:678-81.
39. Chojkier M, Conn HO. Esophageal tamponade in the treatment of bleeding varices. A decadel progress report. Dig Dis Sci 1980;25:267-72.
40. Azoulay D, Castaing D, Majno P, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol 2001;35:590-7.
41. Bizollon T, Dumortier J, Jouisse C, et al. Transjugular intrahepatic portosystemic shunt for refractory variceal bleeding. Eur J Gastroenterol Hepatol 2001;13:369-75.
42. Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996;111:138-46.
43. Jalan R, John TG, Readhead DN, et al. A comparative study of emergency transjugular intrahepatic portosystemic stent-shunt and esophageal transection in the management of uncontrolled variceal hemorrhage. Am J Gastroenterol 1995;90:1932-7.
44. Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural history of gastric varices: a long term follow up study in 568 portal hypertension patients. Hepatology 1992;16:1343-9.
45. Trudeau W, Prindiville T. Endoscopic injection sclerosis in bleeding gastric varices. Gastrointest Endosc 1986;32:264-8.
46. Chiu KW, Changchien CS, Chuah SK, et al. Endoscopic injection sclerotherapy with 1.5% sotradecol for bleeding cardiac varices. J Clin Gastroenterol 1997;24:161-4.
47. Ogawa K, Ishikawa S, Naritaka Y, et al. Clinical evaluation of endoscopic injection sclerotherapy using N-butyl-2-cyanoacrylate for gastric variceal bleeding. J Gastroenterol Hepatol 1999;14:245-50.
48. Barange K, Peron JM, Imani K, et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology 1999;30(5):1139-43.
49. Stanley AJ, Jalan R, Ireland HM, Redhead DN, Bouchier IA, Hayes PC. A comparison between gastric and oesophageal variceal haemorrhage treated with transjugular intrahepatic portosystemic stent shunt (TIPSS). Aliment Pharmacol Ther 1997;11:171-6.
50. Tripathi D, Helmy A, Macbeth K, et al. Ten years follow-up of 472 patients following transjugular intrahepatic portosystemic stent-shunt insertion at a single centre. Euro J of Gastroenterol and Hepatol 2004;16(1):9-18.
51. Lo GH, Lai KH, Cheng JS, Chen MH, Chiang HT. A prospective randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001;33:1060-4.
52. Yang WL, Tripathi D, TherapondosG, Todd A, Hayes PC. Endoscopic use of human thrombin in bleeding gastric varices. AmJ Gastroenterol 2002;97:1381-5.
53. Hirota S, Matsimoto S, Tomita M, Sako M, Kono M. Retrograde transvenous obliteration of gastric varices. Radiology 1999;211:349-56.
54. Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 1996;11:51-8.
55. Matsumoto A, Hamamoto N, Nomura T, et al. Balloon-occluded retrograde transvenous obliteration of high risk gastric fundal varices. Am J Gastroenterol 1999;94:643-9.
56. Choi YH, Yoon CJ, Park JH, Chung JW, Kwon JW, Choi GM. Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunts. Korean Journal of Radiology 2003;4:109-16.
57. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-9.
58. Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982;82:968-73.
59. de Franchis R, Primigani M. Why do varices bleed? Gastroenterol Clin North Am 1992;21:85-101.
60. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997;25:63-70.
61. Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal bleeding. Hepatology 2000;31:1239-45.
62. Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Eng J Med 1996;334:1624-9.
63. Bureau C, Peron JM, Alric L, et al. "A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Gastroenterology 2003;124:1993-5. (comment)
64. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-54.
65. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol 1997;26:312-24.
66. Lo GH, Lai KH, Cheng JS, et al. A prospective randomized trial of sclerotherapy vs. ligation in the management of bleeding esophageal varices. Hepatology 1995;22:466-71.
67. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med 1995;123:280-7.
68. Lo GH, Chen WC, Chen MH, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002;123(3):728-34.
69. Patch D, Sabin CA, Goulis J, et al. A randomized controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002;123(4):1013-9.
70. Villanueva C, Minana J, Oritz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Eng J Med 2001;345:647-55.
71. Vinel JP, Lamouliatte H, Cales P, et al. Propranolol reduces the rebleeding rate during endoscopic sclerotherapy before variceal obliteration. Gastroenterology 1992;102:1760-3.
72. Avgerinos A, Rekoumis G, Klonis C, et al. Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy: a randomized controlled trial. J Hepatol 1993;19:301-11.
73. Lo G-H, Lai K-H, Cheng J-S, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective randomized trial. Hepatology 2000;32:461-5.
74. Singh P, Pooran N, Indaram A, Bank S. Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a meta-analysis. American Journal of Gastroenterology 2002;97:623-9.
75. Nakamura S, Mitsunaga A, Murata Y, Suzuki S, Hayashi N. Endoscopic induction of mucosal fibrosis by argon plasma coagulation (APC) for esophageal varices: a prospective randomized trial of ligation plus APC vs. ligation alone. Endoscopy 2001;33(3):210-5.
76. Cipolletta L, Bianco MA, Rotondano G, Marmo R, Meucci C, Piscopo R. Argon plasma coagulation prevents variceal recurrence after band ligation of esophageal varices: preliminary results of a prospective randomized trial. Gastrointest Endosc 2002;56:600-3. (comment)
77. Escorsell A, Banares R, Garcia-Pagan JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized control trial. Hepatology 2002;35:385-92.
78. Tripathi D, Lui HF, Helmy A, et al. Randomized controlled trial of long term portographic follow up versus variceal band ligation following transjugular intrahepatic portosystemic stent shunt for prevention of oesophageal variceal rebleeding. Gut 2003;000:1-7.
79. Riggio O, Merlli M, Pedretti G, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci 1996;41:578-84.
80. Sanyal AJ, Freedman AM, Shiffmann ML, Purdum PP III, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study. Hepatology 1994;20:46-55.
81. Poynard T, Cales P, Pasta L, et al. Beta adrenergic antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: an analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Eng J Med 1991;324:1532-8.
82. Pagliaro L, D'Amico G, Sorensen TI, et al. Prevention of first bleeding in cirrhosis: a meta-analysis of randomized trials of nonsurgical treatment. An Intern Med 1992;117:59-70.
83. Teran JC, Imperiale TF, Mullen KD, Tavill AS, McCullough AJ. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Gastroenterology 1997;112;473-82.
84. Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: a randomized controlled study. Ann Intern Med 1991;114:869-73.
85. Garcia-Pagan J, Villanueva C, Vila M, et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot tolerate beta blockers. Gastroenterology 2001;121:908-14.
86. Lui HF, Stanley AJ, Forrest EH, et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002;123:735-44.
87. Imperiale T, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001;33:802-7.